Details of Drug-Drug Interaction
| Drug General Information (ID: DDIERF3JB2) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Heparin | Drug Info | Telavancin | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Anticoagulants | Glycopeptide Antibiotics | |||||||
| Structure | |||||||||
| Mechanism of Heparin-Telavancin Interaction (Severity Level: Major) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph | |||||||||
| Drug Name | Heparin | Telavancin | |||||||
| Mechanism | Heparin | Prolong activated partial thromboplastin time (aPTT) test results | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Pharmacodynamics | ||||||||
| Factor Description | Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Concomitant use of telavancin and intravenous unfractionated heparin sodium is considered contraindicated. For patients who require aPTT monitoring while being treated with telavancin, a non-phospholipid dependent coagulation test such as a Factor Xa (chromogenic) assay or an alternative anticoagulant not requiring aPTT monitoring may be considered. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Vibativ (telavancin). Theravance Inc, South San Francisco, CA. | ||||||||||||||||||